drugset / Trial / NCT00837824
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
RandomizedParallel-groupOpen-labelTreatment
Summary
This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
Timeline
- Start
- 2002-12
- Primary completion
- 2003-08
- Completion
- 2003-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | agalsidase beta | Protein / enzyme biologic | 1 mg/kg | — |
| Subject | agalsidase beta | Protein / enzyme biologic | 3 mg/kg | — |